More context, better questions

NAD+ is a coenzyme involved in cellular metabolism, not a peptide. It appears in many peptide-oriented catalogs because of interest in wellness and aging. Keeping that classification clear prevents readers from assuming that all compounds in a catalog share the same chemistry or clinical evidence.

Epitalon is a synthetic tetrapeptide often discussed in longevity research. Its association with telomeres has led to broad online claims about slowing aging. The ability to change a laboratory marker is much narrower than proof that a treatment extends healthy human life.

NAD cycles between chemical states in energy-related reactions and serves as a substrate for several enzyme systems. The fact that cells require NAD does not demonstrate that an infusion improves health in a person without a defined deficiency or indication. Different precursors and delivery routes create different biological questions.

Cell experiments investigate telomerase activity and telomere maintenance. Telomeres are structures at chromosome ends, and their biology is complex. Longer telomeres in a cell culture are not a direct measurement of a person’s biological age, and telomerase activation cannot be assumed to produce an uncomplicated health benefit.

Human investigations include measurements of metabolism and tolerability, but these should not be turned into broad proof of improved longevity, cognitive performance, or recovery. A study of an oral precursor is not a study of intravenous NAD+, and a retrospective clinic series is not equivalent to a blinded randomized trial.

Published experiments report effects in cultured human cells, including work on telomerase and telomere length. These are not clinical lifespan trials. Historical reports involving pineal extracts or epithalamin should also be separated from studies of the defined synthetic epitalon sequence, since they are not necessarily equivalent interventions.

Wellness claims often combine findings from cells, animals, precursor supplements, and infusion services into one narrative. Those exposures must be separated. An increase in a blood biomarker also does not prove the compound reached every tissue of interest or changed a meaningful clinical outcome.

Longevity claims require evidence on meaningful outcomes such as disease, function, and survival, with adequate follow-up and controls. A cell’s division history is not the same as the health trajectory of an organism. Mechanistic enthusiasm should therefore be accompanied by clear statements about what has not been demonstrated in people.

Infusions have procedure-related risks in addition to potential pharmacologic effects. Product preparation, vascular access, rate of administration, and medical history matter. A supervised service is not automatically an evidence-based indication, and a pleasant short-term experience cannot establish long-term benefit or exclude uncommon harms.

Long-term effects of manipulating telomere-related pathways remain uncertain. Unapproved products add questions about identity, purity, dose accuracy, and sterility. The absence of a well-established adverse-event rate is not evidence that repeated courses are safe, particularly for users with complex medical histories.

NAD+ should not be described as an FDA-approved anti-aging infusion. Regulatory and evidence questions depend on the exact product, route, and claim. Endogenous presence is not an approval category.

Epitalon is not an FDA-approved general anti-aging or life-extension medicine. FDA has considered related bulk-substance questions, but a nomination or advisory discussion does not establish clinical approval.